DrugPatentWatch Database Preview
Fostamatinib disodium - Generic Drug Details
What are the generic sources for fostamatinib disodium and what is the scope of patent protection?
Fostamatinib disodium
is the generic ingredient in one branded drug marketed by Rigel Pharms Inc and is included in one NDA. There are fourteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.Fostamatinib disodium has one hundred and one patent family members in forty countries.
One supplier is listed for this compound.
Summary for fostamatinib disodium
| International Patents: | 101 |
| US Patents: | 14 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 51 |
| Clinical Trials: | 18 |
| Patent Applications: | 8 |
| DailyMed Link: | fostamatinib disodium at DailyMed |
Recent Clinical Trials for fostamatinib disodium
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Rigel Pharmaceuticals | Phase 3 |
| AstraZeneca | Phase 2 |
| AstraZeneca | Phase 3 |
Synonyms for fostamatinib disodium
| 1025687-58-4 |
| 1025687-58-4, Fostamatinib disodium, R935788 |
| 6-[[5-Fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]-2,2-dimethyl-4-[(phosphonooxy)methyl]-2h-pyrido[3,2-b]-1,4-oxazi n-3(4h)-one sodium salt |
| 6-[[5-Fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]-2,2-dimethyl-4-[(phosphonooxy)methyl]-2H-pyrido[3,2-b]-1,4-oxazin-3(4H)-one sodium salt |
| AB0029942 |
| AC-28433 |
| AK546934 |
| AKOS026750559 |
| AOB87147 |
| AS-16263 |
| BC659976 |
| C23H24FN6O9P2Na |
| C23H26FN6O9P |
| cc-28 |
| CHEMBL2105644 |
| CS-0427 |
| disodium [6-({5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}amino)-2,2-dimethyl-3-oxopyrido[3,2-b][1,4]oxazin-4-yl]methyl phosphate |
| disodium,[6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-3-oxopyrido[3,2-b][1,4]oxazin-4-yl]methyl phosphate |
| DTXSID70145275 |
| EX-A2146 |
| Fostamatinib disodium anhydrous |
| Fostamatinib/R788 |
| HY-13038 |
| J-000725 |
| J-518183 |
| KS-00000TSG |
| R 788 sodium |
| R 935788 |
| R 935788 sodium |
| R-788 disodium |
| R-935788 |
| R788 (Fostamatinib) Disodium |
| R788 disodium |
| R788 disodium (Fostamatinib) |
| R788 SODIUM |
| R788, Fostamatinib |
| R788(Disodium); Fostamatinib Disodium |
| R788(Fostamatinib disodium) |
| R788(Fostamatinib-disodium) |
| R788(prodrug of R406) |
| R935788 - Fostamatinib disodium |
| R935788 (Fostamatinib disodium, R788) |
| R935788 (Fostamatinib disodium) |
| RL00119 |
| S-7667 |
| SC-85814 |
| SCHEMBL3657651 |
| sodium (6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)pyrimidin-4-yl)amino)-2,2-dimethyl-3-oxo-2,3-dihydro-4H-pyrido[3,2-b][1,4]oxazin-4-yl)methyl phosphate |
| Tamatinib fosdium |
| Tube731 |
| UNII-X9417132K8 |
| X2110 |
| X9417132K8 |
| Y0280 |
US Patents and Regulatory Information for fostamatinib disodium
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rigel Pharms Inc | TAVALISSE | fostamatinib disodium | TABLET;ORAL | 209299-002 | Apr 17, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Rigel Pharms Inc | TAVALISSE | fostamatinib disodium | TABLET;ORAL | 209299-001 | Apr 17, 2018 | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | |||
| Rigel Pharms Inc | TAVALISSE | fostamatinib disodium | TABLET;ORAL | 209299-002 | Apr 17, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for fostamatinib disodium
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Brazil | PI0820389 | Start Trial |
| Serbia | 58433 | Start Trial |
| Mexico | 2007007189 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
